BIOGEN PHARMACHEM INDUSTRIES L is a Finance company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 2 | 1 | 0 | 1 | 3 |
| EBITDA (ex other income) | (0) | 0 | (0) | (0) | 1 |
| margin % | (0.7) | 55.0 | — | (34.9) | 37.4 |
| Owners' profit | (0) | 0 | 2 | (0) | 1 |
| EPS, as reported (₹) | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 |
| ROE % · ROCE % | (0.0) · (0.0) | 0.8 · 0.8 | 3.4 · 3.4 | (0.3) · (0.3) | 0.9 · 1.0 |
| Debt / equity (x) | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from operations | 1 | 2 | 2 | (1) | 2 |
| Capex | 0 | 0 | 0 | 0 | 0 |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1 | 2 | 0 | 0 | 1 | 0 |
| Profit before tax | (1) | (0) | 1 | 1 | (0) | 0 | (0) | 0 |
| Net profit | (1) | (0) | 1 | 1 | (0) | 0 | (0) | 0 |
| EPS (₹) | (0.02) | 0.00 | 0.02 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| CRISIL LTD | 34,342 | 38.9 | 10.50 | — | 13.7 | 16.1 | — | 30.6 |
| ONEMI TECHNOLOGY SOL LTD | 5,526 | 19.6 | 4.12 | 9.4 | 21.0 | 18.8 | — | 32.0 |
| GYFTR LIMITED | 1,359 | — | 2.80 | 41.8 | 4.5 | 5.3 | 32.8 | 4.3 |
| CENTRUM CAPITAL LIMITED | 1,077 | — | 0.82 | 9.7 | (21.4) | (2.5) | 49.7 | 29.7 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 4 Sept 2026 · Biogen files Annual Report FY25-26; AGM on Sept 29 via video call | compliance | low | — | — |
| 4 Sept 2026 · Book closure from Sep 22-29 for AGM on Sep 29, 2026 | corporate actions | low | — | — |
| 4 Sept 2026 · Notice of 31st AGM to be held on 29 September 2026 | board shareholder meetings | low | — | — |
| 5 Aug 2026 · Nil disclosure on unutilised issue proceeds as of June 2026 | fund raising | low | — | — |
| 5 Aug 2026 · Biogen Pharmachem Q1 FY27 profit Rs 22.14 lakh; revenue down sharply year on year | results | medium | — | — |
| 5 Aug 2026 · Q1 FY27 results: revenue drops 71 percent, profit falls sharply | results | high | — | — |
| 21 Jul 2026 · Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/08/2026 ,inter alia, to consider and approve Pursuant to Regulation .... | results | low | — | — |
| 7 Jul 2026 · Quarterly compliance certificate submitted to BSE for Apr-Jun 2026 | compliance | minimal | — | — |
| 23 May 2026 · PFA | compliance | minimal | — | — |
| 20 May 2026 · The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Rama Shiva Lease Finance Pvt Ltd | ownership changes | medium | — | — |
| Where a broker report shows | This document shows |
|---|
| PRIME SECURITIES LIMITED |
| 961 |
| 171.5 |
| 3.75 |
| 87.4 |
| 5.1 |
| — |
| 25.7 |
| 19.0 |
| WEALTH FRST PORT. MG. LTD | 900 | 27.3 | 5.29 | 17.3 | 22.5 | 30.3 | — | 97.5 |
| STELLANT SECURITIES (INDIA) LT | 559 | — | 1784.58 | — | 18.2 | 18.2 | — | 56.7 |
| THE INVEST TRUST OF IND L | 511 | 15.3 | 0.70 | 7.1 | 4.7 | 3.9 | (2.4) | 23.4 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 13.5 | 17.9 | 38 of 95 | 61% |
| P/B | 0.3 | 1.2 | 15 of 101 | 85% |
| ROCE | 1.0 | 1.6 | 49 of 84 | 42% |
| ROE | 0.9 | 1.3 | 64 of 115 | 45% |
| Debt / Equity | 0.0 | 0.0 | 4 of 115 | 37% |
| EBITDA margin | 49.9 | 25.6 | 32 of 91 | 66% |
| Revenue growth | (71.3) | (4.1) | 73 of 85 | 14% |
| Profit growth | (83.5) | (0.2) | 86 of 109 | 21% |
| Market cap | 28 | 28 | 54 of 109 | 51% |
| Why |
|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
